JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL

Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of C...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Yumeen, Sara, Mirza, Fatima N., Lewis, Julia M., King, Amber Loren O., Kim, Sa Rang, Carlson, Kacie R., Umlauf, Sheila R., Surovtseva, Yulia V., Foss, Francine M., Girardi, Michael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7252559/
https://ncbi.nlm.nih.gov/pubmed/32437546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001756
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak